Skip to main content
SpringerLink
Log in

Traitements pharmacologiques

  • Chapter
Approche psychiatrique des déviances sexuelles

  • 753 Accesses

Résumé

Bien qu’aucune étude contrôlée n’ait été réalisée chez les patients atteints de paraphilie dans le but d’évaluer l’efficacité des traitements psychotropes, tels que les neuroleptiques de nouvelle ou d’ancienne génération, ou encore les régulateurs de l’humeur, ceux-ci sont parfois utilisés. Des études de cas, ou des études portant sur de petits effectifs, concernant le carbonate de lithium ; les antidépresseurs tricycliques (clomipramine, désipramine), la mirtazapine, les neuro leptiques classiques (benpéridol, thoridazine, halopéridol) ou de nouvelle génération (rispéridone) et enfin les anticonvulsivants (carbamazépine, topiramate, divalproate) ont été publiées (pour revue [1]). Leur utilisation n’est recommandée que lors de l’existence de comorbidités psychiatriques associées à la paraphilie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Thibaut F, Torres de la Barra F, Gordon H et al. (2010) WFBBP Task Force on sexual Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP): guidelines for the biological treatment of paraphilias. World J Biol Psychiatry 11: 604–655 consultable sur www.wfsbp.org

    Article  PubMed  Google Scholar 

  2. Thibaut F, Garcia F (2011) Current concepts in the pharmacotherapy of paraphilias. Drugs 71: 771–790

    Article  PubMed  Google Scholar 

  3. Kafka MP, Prentky R (1992) Fluoxetine treatment of non-paraphilic sexual addictions and paraphilias in men. J Clin Psychiatry 53: 351–358

    PubMed  CAS  Google Scholar 

  4. Kafka MP (1994) Sertraline pharmacotherapy for paraphilias and paraphiliarelated disorders: an open trial. Ann Clin Psychiatry 6: 189–195

    Article  PubMed  CAS  Google Scholar 

  5. Fedoroff JP (1995) Antiandrogens versus serotonergic medications in the treatment of sex offenders: a preliminary compliance study. Can J Hum Sexuality 4: 111–123

    Google Scholar 

  6. Kafka MP, Hennen J (2000) Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. J Clin Psychiatry 61: 664–670

    Article  PubMed  CAS  Google Scholar 

  7. Stein DJ, Hollander E, Anthony DT et al. (1992) Serotonergic medications for sexual obsessions, sexual addictions and paraphilias. J Clin Psychiatry 53: 267–271

    PubMed  CAS  Google Scholar 

  8. Casals-Ariet C, Cullen K (1993) Exhibitionism treated with clomipramine. Am J Psychiatry 150: 1273–1274

    PubMed  CAS  Google Scholar 

  9. Bradford JM, Martindale JJ, Goldberg M et al. (1996) Sertraline in the treatment of pedophilia: an open label study. In New Research Program Abstracts, NR 441, APA Annual Meeting

    Google Scholar 

  10. Greenberg DM, Bradford JM, Curry S et al. (1996) A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: a retrospective study. Bull Am Acad Psychiatry Law 24: 525–532

    PubMed  CAS  Google Scholar 

  11. Phahaj SK (2004) Escitalopram treatment of transvestisc fetishism: case report. German J Psychiatry 7: 20–21

    Google Scholar 

  12. Coleman E, Gratzer T, Nesvacil L et al. (2000) Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: a retrospective study. J Clin Psychiatry 61: 282–284

    PubMed  CAS  Google Scholar 

  13. Thibaut F, Cordier B, Kuhn JM (1993) Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand 87: 445–450

    Article  PubMed  CAS  Google Scholar 

  14. Cooper AJ, Cernovski ZZ (1994) Comparison of cyproterone acetate and leuprolide acetate (LHRH agonist) in a chronic pedophile: a clinical case study. Biol Psychiatry 36(4): 269–271

    Article  PubMed  CAS  Google Scholar 

  15. Bancroft J, Tennent G, Loucas K et al. (1974) The control of deviant sexual behavior by drugs. I. Behavioral changes following estrogens and antiandrogens. Br J Psychiatry 125:310–315

    Article  PubMed  CAS  Google Scholar 

  16. Cooper AJ, Cernovsky ZZ (1992) The effects of cyproterone acetate on sleeping and waking penile erections in pedophiles: possible implications for treatment. Can J Psychiatry 37(1): 33–39

    PubMed  CAS  Google Scholar 

  17. Cooper AJ, Sandhu S, Losztyn S et al. (1992) A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles. Can J Psychiatry 37(10): 687–693

    PubMed  CAS  Google Scholar 

  18. Cooper AJ (1981) A placebo controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Compr Psychiatry 22(5): 458–465

    Article  PubMed  CAS  Google Scholar 

  19. Bradford JM, Pawlak A (1993) Double-blind placebo crossover study of cyproterone acetate in the treatment of the paraphilias. Arch Sex Behav 22(5): 383–402

    Article  PubMed  CAS  Google Scholar 

  20. Laschet U, Laschet L (1975) Antiandrogens in the treatment of sexual deviations of men. J Steroid Biochem 6: 821–826

    Article  PubMed  CAS  Google Scholar 

  21. Davies TS (1974) Cyproterone acetate for male hypersexuality. J Int Med Res 2: 159–163

    PubMed  CAS  Google Scholar 

  22. Rösler A, Witztum E (1998) Treatment of men with paraphilia with a longacting analogue of gonadotropin-releasing hormone. N Eng J Med 338: 416–422

    Article  Google Scholar 

  23. Thibaut F, Cordier B, Kuhn J (1996) Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: a lifetime treatment ? Psychoneuroendocrinology 21(4): 411–419

    Article  PubMed  CAS  Google Scholar 

  24. Thibaut F, Kuhn JM, Cordier B, Petiot M (1998) Hormone treatment of sex offenses. Encephale XXIV: 132–137

    Google Scholar 

  25. Hansen H, Lykke-Olesen L (1997) Treatment of dangerous sexual offenders in Denmark. J Forensic Psychiatry 8: 195–199

    Article  Google Scholar 

  26. Briken P, Nika E, Berner W (2001) Treatment of paraphilia with luteinizing hormone-releasing hormone agonists. J Sex Marital Ther 27(1): 45–55

    Article  PubMed  CAS  Google Scholar 

  27. Briken P (2002) Pharmacotherapy of paraphilias with luteinizing hormonereleasing hormone agonists. Arch Gen Psychiatry 59: 469–470

    Article  PubMed  Google Scholar 

  28. Krueger RB, Kaplan MS (2001) Depot-leuprolide acetate for treatment of paraphilias: a report of twelve cases. Arch Sex Behav 30(4): 409–422

    Article  PubMed  CAS  Google Scholar 

  29. Schober JM, Byrne P, Kuhn PJ (2006) Leuprolide acetate is a familiar drug that may modify sex-offender behaviour: the urologist’s role. BJU Int 97(4): 684–686

    Article  PubMed  CAS  Google Scholar 

  30. Czerny JP, Briken P, Berner W (2002) Antihormonal treatment of paraphilic patients in German forensic psychiatric clinics. Eur Psychiatry 17(2): 104–106

    Article  PubMed  Google Scholar 

  31. Briken P, Hill A, Berner W (2004) A relapse in pedophilic sex offending and subsequent suicide attempt during luteinizing hormone-releasing hormone treatment. J Clin Psychiatry 65(10): 1429

    Article  PubMed  Google Scholar 

  32. Brahams D (1988) Voluntary chemical castration of a mental patient. Lancet 1(8597): 1291–1292

    Article  PubMed  CAS  Google Scholar 

  33. Guay DRP (2009) Drug treatment of paraphilic and non paraphilic sexual disorders. Clin Ther 31(1): 1–31

    Article  PubMed  CAS  Google Scholar 

  34. Keating NL, O’Malley A, Freedland FJ et al. (2010) Diabetes and cardiovascular disease during antiandrogen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102: 39–46

    Article  PubMed  CAS  Google Scholar 

  35. Berlin F (2009) Commentary: Risk/benefit ratio of androgen deprivation treatment for sex offenders. J Am Acad Psychiatry Law 37: 59–62

    PubMed  Google Scholar 

  36. Davies TS (1974) Cyproterone acetate for male hypersexuality. J Int Med Res 2: 159–163

    PubMed  CAS  Google Scholar 

  37. Rousseau L, Couture M, Dupont A et al. (1990) Effect of combined androgen blockade with an LHRH agonist and flutamide in one severe case of male exhibitionism. Can J Psychiatry 35: 338–341

    PubMed  CAS  Google Scholar 

  38. Hoogeveen GH, Van Der Veer E (2008) Side effects of pharmacotherapy on bone with long-acting gonadorelin agonist triptorelin for paraphilia. J Sex Med 5(3): 626–630

    Article  PubMed  CAS  Google Scholar 

  39. Schober JM, Kuhn PJ, Kovacs PG et al. (2005) Leuprolide acetate suppresses pedophilic urges and arousability. Arch Sex Behav 34(6): 691–705

    Article  PubMed  Google Scholar 

  40. Houts FW, Taller I, Tucker DE et al. (2011) Androgen deprivation treatment of sexual behavior. Adv Psychosom Med 31: 149–163

    Article  PubMed  Google Scholar 

  41. Shaw JA (1999) Practice parameters for the assessment and treatment of children and adolescents who are sexually abusive of others (Working Group on Quality Issues). J Am Acad Child Adolesc Psychiatry 38(S12): 55–76

    Google Scholar 

  42. Girardin P, Thibaut F (2004) Epidemiology and treatment of juvenile sex offenders. Pediatric Drugs 6: 79–91

    Article  Google Scholar 

  43. Letourneau EJ, Henggeler SW, Borduin CM et al. (2009) Multisystemic therapy for juvenile sexual offenders: 1-year results from a randomized effectiveness trial. J Fam Psychol. 23(1): 89–102

    Article  PubMed  Google Scholar 

  44. Hanson RK, Gordon A, Harris AJ et al. (2002) First report of the collaborative outcome data project on the effectiveness of psychological treatment for sex offenders. Sex Abuse 14(2): 169–194 discussion 195–7

    PubMed  Google Scholar 

  45. Bradford J, Fedoroff P (2006) Pharmacological treatment of the juvenile sex offender. In Barbaree H, Marshall W: The juvenile sex offender Second Edition. Éd. Guidford Press, Ch 16, pp. 358–382

    Google Scholar 

  46. McConaghy N, Blaszczynski A, Armstrong MS et al. (1989) Resistance to treatment of adolescent sex offenders. Arch Sex Behav. 18(2): 97–107

    Article  PubMed  CAS  Google Scholar 

  47. Ryback RS (2004) Naltrexone in the treatment of adolescent sexual offenders. J Clin Psychiatry. 65(7): 982–986

    Article  PubMed  CAS  Google Scholar 

  48. Travin S, Cullen K, Protter B et al. (1990) Female sex offenders: severe victims and victimizers. J Forens Sci 35: 140–150

    CAS  Google Scholar 

  49. Mellor CS, Farid NR, Craig DF (1988) Female hypersexuality treated with cyproterone acetate. Am J Psychiatr 145: 1037

    PubMed  CAS  Google Scholar 

  50. Chow EW, Choy AL (2002) Clinical characteristics and treatment response to SSRI in a female pedophile. Arch Sex Behav 31: 211–215

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre hospitalier universitaire Charles Nicolle, université de Rouen, Inserm Rouen, France

    Florence Thibaut (Professeur de psychiatrie)

Authors
  1. Florence Thibaut
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Thibaut, F. (2013). Traitements pharmacologiques. In: Approche psychiatrique des déviances sexuelles. Springer, Paris. https://doi.org/10.1007/978-2-8178-0315-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0315-9_7

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0314-2

  • Online ISBN: 978-2-8178-0315-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation